Fab_ IgG(H+L) porc
- Known as:
- Fab_ Immunoglobulin G(H+L) porc
- Catalog number:
- BI 1116
- Product Quantity:
- 4mg/2ml
- Category:
- -
- Supplier:
- P.A.R.I.S
- Gene target:
- Fab_ IgG(+) porc
Related genes to: Fab_ IgG(H+L) porc
- Gene:
- ELDR NIH gene
- Name:
- EGFR long non-coding downstream RNA
- Previous symbol:
- LINC01156
- Synonyms:
- Fabl
- Chromosome:
- 7p11.2
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2014-01-01
- Date modifiied:
- 2017-10-25
Related products to: Fab_ IgG(H+L) porc
Alkaline Phosphatase Conjugated Affinity Purified anti-Swine IgG (H&L) [Goat] Secondary_Antibodies Alkaline Phosphatase Conjugated Affinity Purified anti_Swine IgG (H&L) [Goat](5-Lactoglobulin IgG ELISA, Allergies(Arg8)-Vasopressin - Purified Antiserum - IgG(Arg8)-Vasopressin - Purified Antiserum - IgG, Host Rabbit(Arg8)-Vasopressin - Purified Antiserum - IgG, Host Rabbit(Arg8)-Vasopressin - Purified Antiserum - IgG, Host: Rabbit(Arg8)-Vasopressin - Purified Antiserum - IgG, Host: Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(Arg8)_Vasopressin _ Purified Antiserum _ IgG, Host Rabbit(D-Ser(tBu)6,Azagly10)-LHRH (Goserelin) - Purified Antiserum - IgG(D-Ser(tBu)6,Azagly10)-LHRH (Goserelin) - Purified Antiserum - IgG, Host Rabbit(D-Ser(tBu)6,Azagly10)-LHRH (Goserelin) - Purified Antiserum - IgG, Host Rabbit Related articles to: Fab_ IgG(H+L) porc
- Although the outcomes of endoluminal lacrimal duct recanalization (ELDR) for nasolacrimal duct (NLD) obstruction are associated with the obstruction length, NLD obstruction has not been quantified. In this study, we aimed to quantify the obstruction length using a calibrated dacryoendoscope and investigate its relationship with surgical outcomes following endoscopic recanalization of the lacrimal passage. We retrospectively analyzed the eyes of patients who underwent ELDR using a calibrated dacryoendoscope at our institution between January 2023 and February 2025. Patients with dacryocystitis detected during preoperative irrigation testing were excluded. A lacrimal tube was placed for 2 months after recanalization, and we used the calibrated dacryoendoscope to measure the obstruction length. The 3-month postoperative outcomes were determined using irrigation testing, subjective symptoms, and cotton thread testing. A total of 31 eyes of 26 patients (6 eyes of 5 males; 25 eyes of 21 females; mean age, 68.8 ± 10.5 years) were included in this study. The mean obstruction length was 10.8 mm (range: 1-30 mm). The nasolacrimal duct was patent, showed reflux, and was obstructed in 12, 16, and 3 eyes, respectively, at 3 months. The symptoms resolved, improved, and remained unchanged in 18, 11, and 2 eyes, respectively. Trend analysis revealed a significant relationship between the obstruction length and irrigation outcomes. However, no significant association was observed with the symptoms. The obstruction length was significantly correlated with the 3-month postoperative cotton thread test results. The NLD obstruction length was associated with the 3-month postoperative irrigation test results, and longer obstruction was associated with poorer postoperative outcomes. - Source: PubMed
Publication date: 2026/01/20
Ueta YoshikiWatanabe YujiTanaka NobuyaTanaka Anzu - Bladder cancer (BCa) is one of the most prevalent genitourinary malignancies with high recurrence worldwide. A lack of reliable prognostic biomarkers and effective therapeutic targets hinders its treatment. Emerging evidence indicates that long noncoding RNAs (lncRNAs) are involved in human cancers, including BCa. While lncRNAs hold enormous promise, their specific roles and mechanisms in BCa remain largely unexplored. Here, we identify the lncRNA ELDR as a pivotal oncogenic driver in BCa. - Source: PubMed
Publication date: 2025/11/21
Hu XiaoXie TianhangXiao XiaoMei Yuhua - Lysosomal adaptation through the endo-lysosomal damage response (ELDR) enables cancer cells to evade lysosome-targeted therapies. Here, we identified the flavonoid compound V8 as a first-in-class ELDR disruptor that eliminated cancer cells by sabotaging lysosomal resilience. Mechanistically, V8 bound lysosomal HSP70 via hydrogen bonding, destabilizing its interaction with bis(monoacylglycero)phosphate (BMP) and triggering pathological sphingomyelin (SM) accumulation. SM overload allosterically inhibited TRPML1, blocking calcineurin PPP3CB activation and subsequent TFEB dephosphorylation. This dual perturbation: enhanced lysophagy and failed TFEB-driven biogenesis drove catastrophic lysosomal bankruptcy. Crucially, V8 bypassed canonical ELDR activation: unlike lysosomotropic agent LLOMe, it induced global membrane remodeling rather than focal perforations, avoiding Ca²⁺-dependent endosomal sorting complexes required for transport (ESCRT) repair. Genetic validation using HSP70-knockout and point mutation models confirmed target specificity, while SM synthase inhibition rescued TRPML1 activity and mitigated apoptosis. Tumor-selective efficacy arose from malignant cells' heightened SM dependency and lysosomal HSP70 reliance, sparing normal counterparts. Our work established HSP70-BMP-ASM axis disruption as a strategy to subvert lysosomal homeostasis, providing a blueprint for next-generation lysosome-targeting agents that exploit lipid-mediated channelopathy to sensitize cancer cells to lysosomal damage. - Source: PubMed
Publication date: 2025/12/05
Chen HongyuZhu MengyuanZhao ZiyingJiang YuexinWang HaidiLiu YuChen YanLi HuiXun ChenHui Hui - To examine the clinical characteristics and surgical outcomes of patients with Down syndrome (DS) presenting with primary epiphora. - Source: PubMed
Publication date: 2025/11/19
Nakamura JutaroAsano MizukiOhno TomokoGoto SatoshiMizuki NobuhisaMatsumura Nozomi - Acute myeloid leukemia (AML) with rearrangement of the mixed lineage leukemia gene expresses MLL-AF9 fusion protein, a transcription factor that impairs differentiation and drives expansion of leukemic cells. In this work, the zinc finger protein "growth factor independent 1" together with the histone methyltransferase LSD1 is revealed to occupy the promoter and regulate the expression of the lncRNA ELDR (EGFR [epidermal growth factor receptor] long non-coding downstream RNA) in the rearranged Mixed Lineage Leukemia (MLL) (MLL-r) AML cell line THP-1. Forced ELDR overexpression enhanced the growth inhibition of an Lysine-Specific Demethylase 1 inhibitor (LSD1i)/all-trans retinoic acid (ATRA) combination treatment and reduced the capacity of these cells to generate leukemia in xenografts, leading to a longer leukemia-free survival. ELDR is found to bind the clamp protein Proliferating Cell Nuclear Antigen (PCNA) and the MCM5 helicases causing defects of DNA replication fork progression. Moreover, AML cells overexpressing ELDR had reduced chromatin accessibility and transcription at α-satellite repeats in centromeres. In addition, ELDR RNA was detected close to MLL-AF9 at centromeres suggesting that it impedes leukemic progression preferentially of MLL-r AML by interfering with both DNA replication and centromeric transcription. Our findings reveal novel functions of the lncRNA ELDR in DNA replication and centromere biology when expressed at high levels in AML cells with MLL rearrangements. These discoveries could provide rationale for future strategies to treat MLL-r AML, which has a poor prognosis in children and adults. Delivery of the ELDR RNA could potentially be used as an adjunct to LSD1i/ATRA treatment or other currently used chemotherapeutic drugs to develop novel therapies for these AML subtypes. - Source: PubMed
Arman KaifeeRoss JuliePiskor Eva-MariaLazzari LucaCalderon VirginieReulet GaspardVera MariaSt-Hilaire EdlieWurtele HugoWilhelm Brian TMöröy Tarik